VHH antibody is a promising next-generation therapeutic antibody technology for cancer immunotherapy and other applications. VHH antibodies are distinguished from other conventional antibody formats by their unique properties of size, solubility, intrinsic stability, easy tailoring into pluripotent constructs, recognition of uncommon or hidden epitopes, binding into cavities or active sites of enzyme targets, ease and speed of drug discovery, and ease of manufacture.
BioIntron is a well-recognized leader in the field of single domain antibody discovery. Based on our advanced phage display technology, our scientists are specialized in the production and discovery of specific single domain antibodies.